InVivo Therapeutics Featured In Life Science Leader

- Industry Veteran Wayne Koberstein Interviews CEO and Chairman Mark Perrin -

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company was featured in a Life Science Leader article titled “InVivo Therapeutics: Taking on Spinal Cord Injury” as part of The Enterprisers series.

“Wayne has a real talent for distilling the complex world of therapeutic development and effortlessly bringing in the human element”

Wayne Koberstein, Executive Editor of the Life Science Leader magazine and 25-year veteran of the publishing industry, interviewed Mark Perrin, InVivo’s Chief Executive Officer and Chairman. Mr. Koberstein has interviewed and profiled over 200 top executives in pharmaceutical companies as well as influential regulatory and healthcare leaders around the world. In 2002, he won the highest business journalism award in the United States, the Grand Neal, by the American Business Media Association.

“Wayne has a real talent for distilling the complex world of therapeutic development and effortlessly bringing in the human element,” Mr. Perrin said. “It was a pleasure to be interviewed by him and to share the tremendous progress made by InVivo over the last two years."

To view the article, please visit: http://www.lifescienceleader.com/doc/invivo-therapeutics-taking-on-spinal-cord-injury-0001

Life Science Leader magazine is a publication intended to help facilitate connections and foster collaborations in pharmaceutical and medical device developments to find ways to get more life-saving and life-improving therapies to market in an efficient manner. The publication has a circulation of 25,000 professionals in the life sciences, pharmaceutical, biopharmaceutical, and medical device industries.

About the Neuro-Spinal Scaffold™ Implant

Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "believe," "anticipate," "intend," "estimate," "will," "may," "should," "expect," “designed to,” “potentially,” and similar expressions, and include statements regarding the safety and effectiveness of the Neuro-Spinal Scaffold and expected future studies involving the Neuro-Spinal Scaffold. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the company’s ability to successfully open additional clinical sites for enrollment and to enroll additional patients; the timing of the Institutional Review Board process; the company’s ability to commercialize its products; the company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the company’s products and technology in connection with the treatment of spinal cord injuries; the availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the company’s Annual Report on Form 10-K for the year ended December 31, 2015, and its other filings with the SEC, including the company’s Form 10-Qs and current reports on Form 8-K. The company does not undertake to update these forward-looking statements.